[1] |
李琦, 李涛, 范羽, 等. PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义[J]. 肿瘤预防与治疗, 2018, 31(4)248-257
|
|
LI Q, LI T, FAN Y, et al. Expression of PD-1/PD-L1 in esophageal squamous cell carcinoma and its clinical significance[J]. J Cancer Control Treat, 2018, 31(4)248-257
|
[2] |
王程浩, 韩泳涛. 2020年中国临床肿瘤学会《食管癌诊疗指南》解读[J]. 肿瘤预防与治疗, 2020, 33(4): 285-290.
|
|
WANG C H, HAN Y T. Interpretation of the 2020 guidelines for the diagnosis and treatment of esophageal cancer by Chinese society of clinical oncology[J]. J Cancer Control Treat, 2020, 33(4): 285-290.
|
[3] |
SHAH M A, KOJIMA T, HOCHHAUSER D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019, 5(4): 546-550.
doi: 10.1001/jamaoncol.2018.5441
pmid: 30570649
|
[4] |
KOJIMA T, SHAH M A, MURO K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148.
doi: 10.1200/JCO.20.01888
|
[5] |
HUANG Z L, JIN Y, CAI X, et al. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer[J]. Thorac Cancer, 2022, 13(4): 523-532.
doi: 10.1111/tca.v13.4
|
[6] |
GUO W, WANG P, LI N, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis[J]. Oncotarget, 2018, 9(17): 13920-13933.
doi: 10.18632/oncotarget.23810
pmid: 29568405
|
[7] |
BANG Y J, RUIZ E Y, VAN CUTSEM E, et al. Phase Ⅲ, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300[J]. Ann Oncol, 2018, 29(10): 2052-2060.
doi: 10.1093/annonc/mdy264
|
[8] |
MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6): 717-726.
doi: S1470-2045(16)00175-3
pmid: 27157491
|
[9] |
JANJIGIAN Y Y, BENDELL J, CALVO E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844.
doi: 10.1200/JCO.2017.76.6212
pmid: 30110194
|
[10] |
LEONE A G, PETRELLI F, GHIDINI A, et al. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score[J]. ESMO Open, 2022, 7(1): 100380.
doi: 10.1016/j.esmoop.2021.100380
|
[11] |
HIRSCH F R, MCELHINNY A, STANFORTH D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol, 2017, 12(2): 208-222.
doi: S1556-0864(16)33536-5
pmid: 27913228
|
[12] |
TSAO M S, KERR K M, KOCKX M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project[J]. J Thorac Oncol, 2018, 13(9): 1302-1311.
doi: S1556-0864(18)30626-9
pmid: 29800747
|
[13] |
KRIGSFELD G S, ZERBA K, NOVOTNY J Jr, et al. A comparative study of the PD-L1 IHC 22C3 and 28-8 assays on lung cancer samples[J]. Int J Radiat Oncol, 2019, 104(1): 236-237.
|
[14] |
WATANABE T, OKUDA K, MURASE T, et al. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma[J]. Oncotarget, 2018, 9(29): 20769-20780.
doi: 10.18632/oncotarget.25100
pmid: 29755688
|
[15] |
DE RUITER E J, MULDER F J, KOOMEN B M, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)[J]. Mod Pathol, 2021, 34(6): 1125-1132.
doi: 10.1038/s41379-020-0644-7
|
[16] |
KRIGSFELD G S, PRINCE E, ZERBA K, et al. Analysis of real-world PD-L1 testing in patients with urothelial carcinoma[J]. J Clin Oncol, 2019, 37(7_suppl): 447.
|
[17] |
KARNIK T, KIMLER B F, FAN F, et al. PD-L1 in breast cancer: comparative analysis of 3 different antibodies[J]. Hum Pathol, 2018, 72: 28-34.
doi: S0046-8177(17)30281-2
pmid: 28843709
|
[18] |
ADAM J, LE STANG N, ROUQUETTE I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer[J]. Ann Oncol, 2018, 29(4): 953-958.
doi: S0923-7534(19)45464-1
pmid: 29351573
|
[19] |
BÜTTNER R, GOSNEY J R, SKOV B G, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer[J]. J Clin Oncol, 2017, 35(34): 3867-3876.
doi: 10.1200/JCO.2017.74.7642
pmid: 29053400
|
[20] |
UDALL M, RIZZO M, KENNY J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics[J]. Diagn Pathol, 2018, 13(1): 12.
doi: 10.1186/s13000-018-0689-9
pmid: 29426340
|